Pursuant to Reg. 30 of SEBI (LODR) Reg 2015, Find enclosed herewith the copy of press release made to analysts and investors in connection with Audited Standalone & Consolidated Financial ....
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natural Capsules reported Q4FY26 revenue of ₹5.45 crore (up 30% QoQ, up 157% YoY), driven by dispatch of previously deferred goods from the Puducherry plant shutdown. However, EBITDA margin contracted sharply to 2.28% (down 844 basis points QoQ) and the company posted a PAT loss of ₹4.98 crore. For full year FY26, revenue stood at ₹187.20 crore with significant losses - PAT loss of ₹24.66 crore and negative EBITDA margin of 0.83%. Management attributed Q4 strength to one-time dispatches worth approximately ₹6 crore that carried higher profitability as associated costs were absorbed in the prior quarter. The company launched commercial API sales in Q4 and signed a collaboration with Fermbox Bio for fermentation-based CDMO services at its Natural Biogenex subsidiary. A new HPMC line for double-zero capsules is ready, with revenue expected from H2 FY27 pending US client approvals.
The stock faces pressure from heavy full-year losses and margin contraction, though Q4 showed operational recovery. FY27 guidance of stability in capsules with API scaling provides modest optimism, but the company needs to improve margins meaningfully to restore investor confidence.